Clinical trial
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
NCT00418938 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00418938 |
|---|---|
| Title | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial |
| Official title | A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer, Rectal Cancer, Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Panitumumab, Bevacizumab, Leucovorin, Irinotecan, 5-Fluorouracil |
| Enrollment | 266 |
| Start date | Nov 1, 2006 |
| Primary completion | May 10, 2012 |
| Completion | Apr 1, 2013 |
| First posted | Jan 5, 2007 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: